Roche enters RNA exon editing deal with Ascidian
License out/inFast Track
Roche has signed a research collaboration and licensing agreement with Boston-based biotech startup Ascidian Therapeutics aimed at the discovery and development of RNA exon editing therapeutics targeting neurological diseases.
Ascidian's RNA exon editing platform is designed to expand the therapeutic possibilities of RNA medicine by replacing multiple contiguous exons — not just single bases — providing a more versatile RNA therapeutic approach and treating diseases not addressed by today’s gene editing technologies.
The deal gives Roche exclusive, target-specific rights to Ascidian’s RNA exon editing technology for undisclosed neurological targets. In exchange, Ascidian will receive an initial payment of $42 million and is eligible to receive up to $1.8 billion in milestone payments, as well as royalties on commercial sales worldwide.
Back in January, the FDA greenlighted Ascidian's IND application and granted Fast Track designation for its RNA exon editor in retinal diseases — marking the first time an RNA editor has been cleared in the U.S. to enter the clinic. Ascidian's lead treatment, ACDN-01, is the only clinical-stage therapeutic targeting the genetic cause of Stargardt disease, the most common form of inherited macular degeneration.
This is Roche's second RNA deal of the year. The drugmaker inked a potential $1 billion collaboration with Remix Therapeutics back in January for the discovery and development of small molecule therapeutics that modulate RNA processing using Remix’s REMaster drug discovery platform.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.